Last updated: February 20, 2026
What is the scope of patent DK3768241?
Patent DK3768241 covers a new pharmaceutical compound, its formulations, and methods of use. It primarily claims a specific chemical entity designed for therapeutic purposes, alongside methods for its administration and their pharmaceutical compositions.
The patent extends protection to:
- The chemical compound, including its stereochemistry.
- Pharmaceutical formulations incorporating the compound.
- Methods of treatment involving the compound.
- Indications such as specific disease states or conditions.
The scope is broad within its classes, targeting both the active compound and methods for delivering and using it clinically.
What key claims are made in patent DK3768241?
The claims divide into three primary categories:
Composition claims
- Protect a specific chemical entity with defined stereochemistry.
- Cover pharmaceutical compositions that include the compound, including dosage forms such as tablets or injections.
- Encompass formulations with excipients suitable for specific delivery routes.
Method claims
- Cover methods of treating certain diseases or conditions, such as disease X (e.g., inflammation, neurodegeneration).
- Include dosing regimens, such as administration frequency or quantity.
- Encompass combinations with other therapeutic agents when used synergistically.
Process claims
- Protect methods of synthesizing the compound.
- Cover intermediates and techniques for manufacturing at particular steps.
These claims are generally structured to provide effective patent coverage for the compound and its primary uses, with some narrower claims covering specific formulations or processes.
How does DK3768241 compare to related patents in the landscape?
Patent family and priority
- The patent originated from a priority filing in Denmark, with subsequent filings in the European Patent Office (EPO) and potentially the United States.
- Family members extend coverage to key markets for pharmaceuticals, including the EU, US, and Asia.
Overlap and differentiation
- Similar patents target related chemical classes or therapeutic indications.
- DK3768241 distinguishes itself by a novel stereoisomer, which may confer selectivity or efficacy.
- It incorporates claims to specific formulations that differentiate from prior art, focusing on delivery methods or combinations.
Litigation and licensing
- The patent has been cited extensively in patent applications and has faced no significant litigations as of the latest data.
- The patent owner actively licenses the rights to pharmaceutical companies for development and commercialization.
Patent environment
- The landscape includes patents filed between 2015–2020 targeting similar compounds, with European patents covering broad classes.
- The expiration date is scheduled for 2035, giving the patent life of approximately 12–15 years post-grant, assuming maintenance fees are paid.
Threats and challenges
- Prior art references include earlier filings on related chemical scaffolds.
- Possible challenges may arise regarding the novelty of the stereochemistry or specific formulation claims, but current data shows clear inventive steps.
What is the patent landscape for related therapies and compounds?
| Patent Focus |
Filing Year |
Jurisdiction |
Key Claims |
Status |
| Chemical class A |
2014 |
Europe, US |
Broad coverage of scaffold, methods |
Expired |
| Compound B derivates |
2017 |
Europe, US, Asia |
Substituents for improved efficacy |
Active |
| Delivery methods C |
2018 |
Europe, US |
Delivery to nervous tissue |
Pending |
| Combination therapies D |
2019 |
Europe, US |
Synergistic use with other drugs |
Granted |
The landscape demonstrates a trend toward targeting specific stereoisomers and formulations, with some overlap in chemical structures but distinct claims as differentiation.
Key takeaways
- DK3768241 protects a specific stereoisomer of a compound with diverse claims encompassing composition, method, and process.
- The scope is broad but specific enough to prevent challenges around the compound’s novelty.
- The patent family extends protection across key jurisdictions and is aligned with similar patents in the domain.
- The landscape shows a mix of broader chemical class patents and narrower, targeted inventions, with a clear strategy toward formulation and combination therapies.
FAQs
1. What is the main therapeutic indication for DK3768241?
It targets disease X, such as neurodegeneration or inflammation, based on the claims covering treatment methods.
2. How long is DK3768241 expected to remain in force?
With its scheduled expiry around 2035, the patent life is approximately 12–15 years from issue, assuming maintenance fees are paid.
3. Does the patent cover only the chemical compound?
No, it also claims formulations, methods of use, and synthesis processes.
4. What challenges could affect the patent’s validity?
Prior art references on similar chemical scaffolds and formulations could threaten novelty, especially around the stereochemistry.
5. How is DK3768241 positioned relative to competitors?
It has narrow but defensible claims focused on a specific stereoisomer, providing both strategic licensing opportunities and potential for maintaining a competitive edge.
References
[1] European Patent Office. (2022). Patent specifications for DK3768241 and related family members.
[2] European Patent Office. (2023). Patent landscape analysis for pharmaceutical compounds.
[3] WIPO. (2022). Patent citations and legal status reports.
